english.prescrire.org > Spotlight > 100 most recent > Inclisiran (Leqvio°) in certain types of hypercholesterolaemia

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Inclisiran (Leqvio°) in certain types of hypercholesterolaemia

 Marketing Authorisations  Inclisiran is a "small interfering" RNA intended to reduce LDL cholesterol levels in the blood. It has been authorised in the European Union for use in primary or secondary cardiovascular prevention for patients with hypercholesterolaemia, in whom statins are considered insufficiently effective or cannot be used. Does inclisiran reduce the incidence or severity of the cardiovascular complications of hypercholesterolaemia in these situations? Does it represent a therapeutic advance over alirocumab or evolocumab? And what are its adverse effects?
Full article available for download by subscribers

EDITORS' OPINION
Narrow view

When a patient initiates cholesterol-lowering treatment, it is generally intended to be taken for years, with the aim of reducing the risk of premature death and cardiovascular events in the long term...

Full text available for download by subscribers

 ©Prescrire 1 July 2025

Source: "Inclisiran (Leqvio°) in certain types of hypercholesterolaemia" Prescrire Int 2025; 34 (272): 173-175. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook  
 
 
See also:
 
"Evolocumab - Repatha°.
In secondary prevention
of cardiovascular disease:
no reduction in either
all-cause or cardiovascular
mortality"
Prescrire Int 2019;
28 (208): 234-237.
Subscribers only